Stimcell Energetics (STME) Cash from Operations Growth (1y) (2012 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 6.69% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -84.38% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 122.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 185.96% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 16.00% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 28.60% |
| 10 | Stimcell Energetics | - | - | - | -97.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -97.39% |
| Nov 30, 2025 | -348.80% |
| Aug 31, 2025 | -371.89% |
| May 31, 2025 | -81.13% |
| Feb 28, 2025 | -15.21% |
| Nov 30, 2024 | 53.24% |
| Aug 31, 2024 | 43.21% |
| May 31, 2024 | -25.93% |
| Feb 29, 2024 | 63.29% |
| Nov 30, 2023 | 47.71% |
| Aug 31, 2023 | 46.66% |
| May 31, 2023 | 72.91% |
| Feb 28, 2023 | -17.77% |
| Nov 30, 2022 | 42.21% |
| Aug 31, 2022 | 50.00% |
| May 31, 2022 | 36.06% |
| Feb 28, 2022 | 11.12% |
| Nov 30, 2021 | 18.88% |
| Aug 31, 2021 | 10.79% |
| May 31, 2021 | 35.81% |
| Feb 28, 2021 | 54.29% |
| Nov 30, 2020 | 47.71% |
| Aug 31, 2020 | 16.72% |
| May 31, 2020 | -125.86% |
| Feb 29, 2020 | -52.05% |
| Nov 30, 2019 | -1,536.13% |
| Aug 31, 2019 | -337.24% |
| May 31, 2019 | -231.67% |
| Feb 28, 2019 | -66.25% |
| Nov 30, 2018 | 92.51% |
| Aug 31, 2018 | 56.99% |
| May 31, 2018 | 84.14% |
| Feb 28, 2018 | 45.51% |
| Nov 30, 2017 | 19.69% |
| Aug 31, 2017 | 12.14% |
| May 31, 2017 | -131.39% |
| May 31, 2013 | 78.40% |
| Nov 30, 2012 | 50.25% |
| May 31, 2012 | 42.45% |